This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Cytoreduction Followed by Normothermic Versus Hyperthermic Intraperitoneal Intraoperative Chemoperfusion (HIPEC): a Study in Peritoneal Carcinomatosis

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2014 by University Hospital, Ghent.
Recruitment status was:  Recruiting
Sponsor:
Collaborator:
University Ghent
Information provided by (Responsible Party):
University Hospital, Ghent
ClinicalTrials.gov Identifier:
NCT01575730
First received: April 6, 2012
Last updated: December 4, 2014
Last verified: December 2014
  Purpose
Peritoneal carcinomatosis from appendix or colon (large bowel) cancer is treated in suitable patients with surgery followed by instillation of heated chemotherapy inside the abdominal cavity. This procedure is termed 'Hyperthermic intraoperative Peritoneal Chemoperfusion' or HIPEC. Many center perform HIPEC with high dose oxaliplatin, a standard chemotherapy drug active against colon cancer, administered during 30 minutes at 41°C. The hypothesis of this study is, that chemoperfusion at normal (37.5°C) temperature but longer duration (90 minutes) may be safer and at least as efficient. Patients will be treated with one of three possible HIPEC regimens using oxaliplatin: high dose, 30 min, 41°C; high dose, 30 min, 37.5°C; or low dose, 90 min, 37.5°C. The outcome parameters are pharmacokinetic and pharmacodynamic: using specialized techniques, tissue penetration of chemotherapy and cancer cell kill effects will be compared in order to establish the safest and most active HIPEC regimen.

Condition Intervention Phase
Peritoneal Carcinomatosis Procedure: Hyperthermic intraoperative Peritoneal Chemoperfusion Drug: Hyperthermic intraoperative Peritoneal Chemoperfusion Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Study Comparing Normothermic Versus Hyperthermic Intraoperative Chemoperfusion With Oxaliplatin in Patients With Peritoneal Metastases From Appendiceal or Colon Cancer

Resource links provided by NLM:


Further study details as provided by University Hospital, Ghent:

Primary Outcome Measures:
  • Morbidity [ Time Frame: Until discharge or within 30 days ]
    Scoring of postoperative morbidity according to the Dindo-Clavien system

  • Mortality [ Time Frame: Until discharge or within 30 days ]
    The number of deaths will be recorded.

  • Area under the perfusate concentration versus time curve (AUC) of platinum [ Time Frame: Before addition of chemotherapy, at 10, 20 and 30 minutes after addition of chemotherapy ]
    Measurements of platinum in perfusate samples on the high dose interventions.

  • Area under the perfusate concentration versus time curve (AUC) of platinum [ Time Frame: Before addition of chemotherapy, at 10, 20, 30, 40, 50, 60, 70, 80 and 90 minutes after addition of chemotherapy ]
    Measurements of platinum in perfusate samples on the low dose intervention.

  • Area under the plasma concentration versus time curve (AUC) of platinum [ Time Frame: Before addition of chemotherapy, at 10, 20, 30,45, 60, 90 minutes and 2, 4, 8, 12, 18, 24 hours after addition of chemotherapy ]
    Measurements of platinum in perfusate samples on the high dose interventions.

  • Area under the plasma concentration versus time curve (AUC) of platinum [ Time Frame: Before addition of chemotherapy, at 10, 20, 30, 40, 50, 60, 70, 80, 90 minutes and 2, 4, 8, 12, 18, 24 hours after addition of chemotherapy ]
    Measurements of platinum in plasma samples on the low dose intervention.


Secondary Outcome Measures:
  • Tissue Concentration (Cmax) of Platinum [ Time Frame: after 30 or 90 minutes ]
    Platinum concentration will be measured after removal of perfusate.


Estimated Enrollment: 24
Study Start Date: June 2012
Estimated Study Completion Date: July 2015
Estimated Primary Completion Date: July 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Oxaliplatin 37°C, high dose, 30 minutes Procedure: Hyperthermic intraoperative Peritoneal Chemoperfusion
Dose: 460 mg/m², duration: 30 minutes, temperature 37°C
Placebo Comparator: Oxaliplatin 41 °C, high dose, 30 minutes Procedure: Hyperthermic intraoperative Peritoneal Chemoperfusion
Dose: 460 mg/m², duration: 30 minutes, temperature 41°C
Active Comparator: Oxaliplatin 37°C, low dose, 90 minutes Drug: Hyperthermic intraoperative Peritoneal Chemoperfusion
Dose: 200 mg/m², duration: 90 minutes, temperature 37°C

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with peritoneal carcinomatosis from colorectal origin (including appendiceal mucinous neoplasms and the pseudomyxoma syndromes) amenable for cytoreduction and HIPEC.

Exclusion Criteria:

  • No written informed consent
  • Irresectable and/or metastatic disease found during surgery
  • Known allergy to oxaliplatin
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01575730

Locations
Belgium
Ghent University Hospital Recruiting
Ghent, Belgium
Contact: Wim P Ceelen, MD, PhD       wim.ceelen@ugent.be   
Principal Investigator: Wim P Ceelen, MD, PhD         
Sponsors and Collaborators
University Hospital, Ghent
University Ghent
Investigators
Principal Investigator: Wim P Ceelen, MD, PhD University Hospital, Ghent
  More Information

Additional Information:
Responsible Party: University Hospital, Ghent
ClinicalTrials.gov Identifier: NCT01575730     History of Changes
Other Study ID Numbers: 2012/237
2012-000701-77 ( EudraCT Number )
Study First Received: April 6, 2012
Last Updated: December 4, 2014

Keywords provided by University Hospital, Ghent:
Peritoneal carcinomatosis from colorectal or appendiceal origin

Additional relevant MeSH terms:
Carcinoma
Fever
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Body Temperature Changes
Signs and Symptoms
Oxaliplatin
Antineoplastic Agents

ClinicalTrials.gov processed this record on June 23, 2017